HC Wainwright & Co. Reiterates Buy on Cyclo Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cyclo Therapeutics (NASDAQ:CYTH) and maintained a price target of $3.
May 31, 2024 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cyclo Therapeutics and maintained a price target of $3, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Cyclo Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100